Centaurus Financial’s Neurocrine Biosciences NBIX Stock Holding History

Centaurus Financial’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-90	Closed	-$9K	–	1488
2018 Q2	$9K	Buy	+90	New	+$8.06K	﹤0.01%	1599

Other funds holding NBIX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Centaurus Financial's NBIX Position: Q3 2018 in Review

Centaurus Financial sold out of Neurocrine Biosciences (NBIX) in Q3 2018, closing a stake of 90 shares — an estimated $9K sold.

Centaurus Financial first reported a position in NBIX in Q2 2018 and held it in 1 quarter. The position peaked at $9K in Q2 2018. 345 funds tracked by Wall St. Rank hold NBIX as of Q3 2018.

Centaurus Financial reported no remaining Neurocrine Biosciences position as of Q3 2018 after selling out during the quarter.
Centaurus Financial sold 90 Neurocrine Biosciences shares in Q3 2018, an estimated $9K.
Centaurus Financial first reported a position in Neurocrine Biosciences in Q2 2018 and held it in 1 quarter.
Centaurus Financial's Neurocrine Biosciences position peaked at $9K in Q2 2018.
345 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2018.

Based on Centaurus Financial's 13F filing for Q3 2018, filed 5 Nov 2018.